Rhinomed (ASX:RNO) has been accepted as a presenter at 2015 BIO, the world's leading biotech convention to be held in Philadelphia in June.
BIO will be attended by over 15,000 biotech and pharmaceutical industry leaders, including many from Australia, and provides an important opportunity for companies to showcase their research and products.
Rhinomed is a Melbourne-based medical technology company with a patented nasal technology platform that seeks to improve the way people breathe, sleep, maintain health and take medication.
“BIO is a great opportunity to extend the conversations we are already having with a range of parties," said CEO Michael Johnson. "It is also provides a great opportunity to introduce our platform to a much broader set of the world's leading biotech and pharma companies.”
“Rhinomed’s internal nasal platform is rapidly gaining acceptance with thousands of users in both sport and sleep. With this growing level of acceptance, the platform provides a highly attractive, patented and de-risked delivery platform for sleep and drug development companies and pharma,” he said.
The company will be travelling and exhibiting as part of the Victorian Government’s delegation to 2015 BIO.